Evidence map›Paper›PMID 37695315›Full record

ArticleCancer research2023

Oncogenic KRASG12D Reprograms Lipid Metabolism by Upregulating SLC25A1 to Drive Pancreatic Tumorigenesis.

Ruowen Zhang, Xiaogang Peng, James Xianxing Du, Rebecca Boohaker, Igor L Estevao, Brian I Grajeda, Marc B Cox, Igor C Almeida, Weiqin Lu

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Metabolic reprogramming signature predicts immunotherapy efficacy in lung adenocarcinoma: TargetingChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Biomolecules · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ruowen Zhang *Department of Medicine, Stony Brook University, Stony Brook, New York.ORCID 0000-0001-9783-931X
Xiaogang Peng *Depart of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, El Paso, Texas.ORCID 0000-0002-8173-5118
James Xianxing DuDepartment of Medicine, Stony Brook University, Stony Brook, New York.ORCID 0000-0002-8823-0294
Rebecca BoohakerOncology Department, Southern Research Institute, Birmingham, Alabama.ORCID 0000-0003-3387-1876
Igor L EstevaoDepartment of Biological Sciences, Border Biomedical Research Center, University of Texas at El Paso, El Paso, Texas.ORCID 0000-0003-3946-8375
Brian I GrajedaDepartment of Biological Sciences, Border Biomedical Research Center, University of Texas at El Paso, El Paso, Texas.ORCID 0000-0002-1362-4838
Marc B CoxDepart of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, El Paso, Texas.ORCID 0000-0001-7854-2676
Igor C AlmeidaDepartment of Biological Sciences, Border Biomedical Research Center, University of Texas at El Paso, El Paso, Texas.ORCID 0000-0002-2443-8213
Weiqin LuDepartment of Medicine, Stony Brook University, Stony Brook, New York.ORCID 0000-0002-6491-8203
The University of Texas at El Paso · USSouthern Research Institute · USStony Brook University · US

Funding

UTEP Border Biomedical Research CenterU54MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI RENATO J AGUILERA · 2019 to 2026
$35.1M
TCCG12MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI KIRKEN, ROBERT A. · 2012 to 2018
$19.4M
Targeting NADPH Oxidase for Pancreatic Cancer Prevention and TherapyR01CA240818 · NCI · UNIVERSITY OF TEXAS EL PASO · PI LU, WEIQIN · 2020 to 2024
$1.7M
Unraveling the Role of NADPH Oxidase in Inflammation-associated Pancreatic DiseasesR01DK123079 · NIDDK · UNIVERSITY OF TEXAS EL PASO · PI LU, WEIQIN · 2020 to 2024
$1.4M
NCI NIH HHS R01 CA240818NIDDK NIH HHS R01 DK123079NIMHD NIH HHS G12 MD007592NIMHD NIH HHS U54 MD007592
6 · The paper itself

Abstract

Pancreatic cancer is a highly lethal disease with obesity as one of the risk factors. Oncogenic KRAS mutations are prevalent in pancreatic cancer and can rewire lipid metabolism by altering fatty acid (FA) uptake, FA oxidation (FAO), and lipogenesis. Identification of the underlying mechanisms could lead to improved therapeutic strategies for treating KRAS-mutant pancreatic cancer. Here, we observed that KRASG12D upregulated the expression of SLC25A1, a citrate transporter that is a key metabolic switch to mediate FAO, fatty acid synthesis, glycolysis, and gluconeogenesis. In genetically engineered mouse models and human pancreatic cancer cells, KRASG12D induced SLC25A1 upregulation via GLI1, which directly stimulated SLC25A1 transcription by binding its promoter. The enhanced expression of SLC25A1 increased levels of cytosolic citrate, FAs, and key enzymes in lipid metabolism. In addition, a high-fat diet (HFD) further stimulated the KRASG12D-GLI1-SLC25A1 axis and the associated increase in citrate and FAs. Pharmacologic inhibition of SLC25A1 and upstream GLI1 significantly suppressed pancreatic tumorigenesis in KrasG12D/+ mice on a HFD. These results reveal a KRASG12D-GLI1-SLC25A1 regulatory axis, with SLC25A1 as an important node that regulates lipid metabolism during pancreatic tumorigenesis, thus indicating an intervention strategy for oncogenic KRAS-driven pancreatic cancer. SIGNIFICANCE: Upregulation of SLC25A1 induced by KRASG12D-GLI1 signaling rewires lipid metabolism and is exacerbated by HFD to drive the development of pancreatic cancer, representing a targetable metabolic axis to suppress pancreatic tumorigenesis.

Indexed as

Lipid MetabolismPancreatic NeoplasmsAnimalsCarcinogenesisCell Transformation, NeoplasticCitratesFatty AcidsHumansMiceMice, TransgenicMitochondrial ProteinsOrganic Anion TransportersProto-Oncogene Proteins p21(ras)Zinc Finger Protein GLI1CitratesFatty AcidsHras protein, mouseKRAS protein, humanMitochondrial ProteinsOrganic Anion TransportersProto-Oncogene Proteins p21(ras)Slc25a1 protein, humanSlc25a1 protein, mouseZinc Finger Protein GLI1

Identifiers

PMID37695315
PMCPMC10840918
OpenAlexW4386593112

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.